{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T17:03:59Z","timestamp":1786122239122,"version":"build-2736575974"},"reference-count":74,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>This post hoc analysis evaluated the effect of survodutide on beta\u2010cell function, insulin sensitivity, and glucose biomarkers in two phase 2 trial populations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>Trial 1404\u20100002 randomised 413 participants with type 2 diabetes on metformin to receive survodutide, placebo, or semaglutide over 16\u2009weeks. Trial 1404\u20100036 randomised 387 participants with overweight\/obesity and normoglycaemia to receive survodutide or placebo for 46\u2009weeks. Descriptive statistics were derived from both trials. Biomarker responses were analysed using mixed models for repeated measures and regression analysis to assess the impact of bodyweight changes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In trial 1404\u20100002, survodutide was associated with significant and rapid increases in HOMA\u2010\u03b2 versus placebo, with significant decreases in HOMA\u2010IR, glucagon, and fasting plasma glucose (FPG). No significant changes occurred in high\u2010molecular\u2010weight (HMW) adiponectin, C\u2010peptide, or fasting insulin levels. In trial 1404\u20100036, there was no significant change in HOMA\u2010\u03b2 with survodutide versus placebo, likely owing to normoglycaemia in participants. Survodutide was associated with significant decreases in HOMA\u2010IR, glucagon, C\u2010peptide, fasting insulin, and FPG versus placebo, and significant increases in HMW adiponectin. Combining all survodutide dose groups for each trial, absolute change in bodyweight from baseline explained the largest proportion of total variability in changes from baseline in fasting insulin and HOMA\u2010IR. However, it did not explain other changes observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Survodutide was associated with significantly improved beta\u2010cell function and insulin sensitivity in adults with type 2 diabetes and with overweight or obesity. The durability of beta\u2010cell improvements after treatment cessation remains unknown. These effects were largely independent of bodyweight changes, suggesting additional metabolic benefit beyond weight loss.<\/jats:p>\n                    <jats:p>\n                      <jats:bold>Trial Registration:<\/jats:bold>\n                      Trial 1404\u20100002, ClinicalTrials.gov identifier: NCT04153929; EudraCT number: 2019\u2010002390\u201060. Trial 1404\u20100036, ClinicalTrials.gov identifier: NCT04667377; EudraCT number: 2020\u2010002479\u201037.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.70861","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T01:21:11Z","timestamp":1782177671000},"page":"8242-8253","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dual Glucagon and\n                    <scp>GLP<\/scp>\n                    \u20101 Receptor Agonist Survodutide Improves Biomarkers of Beta\u2010Cell Function and Insulin Sensitivity in People With Type 2 Diabetes or Living With Overweight\/Obesity"],"prefix":"10.1111","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2372-395X","authenticated-orcid":false,"given":"Elif I.","family":"Ekinci","sequence":"first","affiliation":[{"name":"Australian Centre for Accelerating Diabetes Innovations (ACADI) The University of Melbourne  Melbourne Victoria Australia"},{"name":"Department of Medicine, Melbourne Medical School The University of Melbourne  Melbourne Victoria Australia"},{"name":"Centre for Research and Education in Diabetes and Obesity (CREDO) and Department of Endocrinology Austin Health  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7723-7027","authenticated-orcid":false,"given":"Sandra Gonz\u00e1lez","family":"Maldonado","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Pharma GmbH &amp; Co. KG  Biberach Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Unseld","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Pharma GmbH &amp; Co. KG  Biberach Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5926-9472","authenticated-orcid":false,"given":"Jorge Arrubla","family":"Martinez","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Pharma GmbH &amp; Co. KG  Ingelheim Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5149-4966","authenticated-orcid":false,"given":"Anita M.","family":"Hennige","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Pharma GmbH &amp; Co. KG  Biberach Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3596-7348","authenticated-orcid":false,"given":"Corinna","family":"Schoelch","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Pharma GmbH &amp; Co. KG  Biberach Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2021.12.012"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1161521"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2022.109860"},{"issue":"9","key":"e_1_2_11_5_1","first-page":"4047","article-title":"Clinical Review 135: The Importance of Beta\u2010Cell Failure in the Development and Progression of Type 2 Diabetes","volume":"86","author":"Kahn S. E.","year":"2001","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-0750"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc24-S008"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(24)00346-2"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.894465"},{"key":"e_1_2_11_10_1","unstructured":"Novo Nordisk Inc WEGOVY (Semaglutide): Prescribing Information 2024 accessed April 25 2025 www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/215256s015lbl.pdf."},{"key":"e_1_2_11_11_1","unstructured":"Novo Nordisk Inc SAXENDA (Liraglutide): Prescribing Information 2024 accessed April 25 2025 www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/206321s019lbl.pdf."},{"key":"e_1_2_11_12_1","unstructured":"Eli Lilly and Co ZEPBOUND (Tirzepatide): Prescribing Information 2025 accessed April 25 2025 www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/217806Orig1s020lbl.pdf."},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.10816"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1124\/pharmrev.123.001045"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2024.2356254"},{"key":"e_1_2_11_16_1","unstructured":"Novo Nordisk Inc OZEMPIC (Semaglutide): Prescribing Information 2025 accessed April 5 2025 www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/209637s025lbl.pdf."},{"key":"e_1_2_11_17_1","unstructured":"Novo Nordisk Inc VICTOZA (Liraglutide): Prescribing Information 2024 accessed April 25 2025 www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/022341Orig1s042lbl.pdf."},{"key":"e_1_2_11_18_1","unstructured":"Novo Nordisk Inc RYBELSUS (Semaglutide Oral): Prescribing Information 2024 accessed April 25 2025 www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/213051s020s021lbl.pdf."},{"key":"e_1_2_11_19_1","unstructured":"Eli Lilly and Co TRULICITY (Dulaglutide): Prescribing Information 2024 accessed April 25 2025 www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/125469s061s062lbl.pdf."},{"key":"e_1_2_11_20_1","unstructured":"Eli Lilly and Co MOUNJARO (Tirzepatide): Prescribing Information 2024 accessed April 25 2025 www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/215866s010s015s022lbl.pdf."},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa863"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae038"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14248734"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-025-01704-z"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-0556"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2025.6112"},{"issue":"10","key":"e_1_2_11_27_1","article-title":"Effect on Hemoglobin A1c (HbA1c) and Body Weight After Discontinuation of Tirzepatide, a Novel Glucose\u2010Dependent Insulinotropic Peptide (GIP) and Glucagon\u2010Like Peptide\u20101 (GLP\u20101) Receptor Agonist: A Single\u2010Center Case Series Study","volume":"15","author":"Kubota M.","year":"2023","journal-title":"Cureus"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15325"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2022.101633"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(23)00356-X"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2401755"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-023-06053-9"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/oby.24184"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2024.09.004"},{"key":"e_1_2_11_35_1","unstructured":"Boehringer Ingelheim A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non\u2010Alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight accessed September 18 2025 https:\/\/clinicaltrials.gov\/study\/NCT06309992."},{"key":"e_1_2_11_36_1","unstructured":"Boehringer Ingelheim LIVERAGE: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH\/MASH Who Have Moderate or Advanced Liver Fibrosis accessed May 30 2025.https:\/\/clinicaltrials.gov\/study\/NCT06632444."},{"key":"e_1_2_11_37_1","unstructured":"Boehringer Ingelheim LIVERAGE \u2013 Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH\/MASH Who Have Cirrhosis accessed May 30 2025 https:\/\/clinicaltrials.gov\/study\/NCT06632457."},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1099451"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-1785"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-017-4289-0"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14890"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.2337\/db23-0356"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.2165\/00024677-200504060-00005"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2023.171003"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.735019"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2023.110779"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(22)00349-7"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00028.2023"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20215407"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.2337\/db12-1116"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2014-1175"},{"issue":"2","key":"e_1_2_11_52_1","first-page":"R501","article-title":"Glucagon in Physiological Concentrations Stimulates Brown Fat Thermogenesis in Vivo","volume":"261","author":"Billington C. J.","year":"1991","journal-title":"American Journal of Physiology"},{"key":"e_1_2_11_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12585"},{"key":"e_1_2_11_54_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41366-022-01223-y"},{"key":"e_1_2_11_55_1","doi-asserted-by":"publisher","DOI":"10.1002\/oby.23141"},{"key":"e_1_2_11_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2021.101484"},{"key":"e_1_2_11_57_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-2151"},{"key":"e_1_2_11_58_1","doi-asserted-by":"publisher","DOI":"10.2337\/db12-0797"},{"key":"e_1_2_11_59_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc23-1287"},{"key":"e_1_2_11_60_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2411528"},{"key":"e_1_2_11_61_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13494"},{"key":"e_1_2_11_62_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13939"},{"key":"e_1_2_11_63_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14394"},{"key":"e_1_2_11_64_1","unstructured":"Altimmune Altimmune Announces Positive Results From Week 24 Interim Analysis of Pemvidutide MOMENTUM Phase 2 Obesity Trial and 12\u2010Week Phase 1b Type 2 Diabetes Safety Trial 2023 accessed July 22 2025 https:\/\/ir.altimmune.com\/news\u2010releases\/news\u2010release\u2010details\/altimmune\u2010announces\u2010positive\u2010results\u2010week\u201024\u2010interim\u2010analysis."},{"key":"e_1_2_11_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01053-X"},{"key":"e_1_2_11_66_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2301972"},{"key":"e_1_2_11_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpha.2023.12.003"},{"key":"e_1_2_11_68_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-060377"},{"key":"e_1_2_11_69_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1327716"},{"key":"e_1_2_11_70_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI29126"},{"key":"e_1_2_11_71_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.102.11.1296"},{"key":"e_1_2_11_72_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20051190"},{"key":"e_1_2_11_73_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14855"},{"key":"e_1_2_11_74_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16052"},{"key":"e_1_2_11_75_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16167"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.70861","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/dom.70861","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dom.70861","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T08:51:20Z","timestamp":1786092680000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.onlinelibrary.wiley.com\/doi\/10.1111\/dom.70861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":74,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1111\/dom.70861"],"URL":"https:\/\/doi.org\/10.1111\/dom.70861","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/DOM.70861\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70861\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70861\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70861\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.70861\/v2\/decision1","asserted-by":"object"}]},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]},"assertion":[{"value":"2026-01-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}